STipe Therapeutics was spun out from Department of Biomedicine at Aarhus University in 2018. The company focuses on enhancing long-term anti-cancer response by activating both innate and adaptive immunity, through a unique sensitizing technology targeting the STING pathway. The company has developed First-in-Class drugs that exploits and strengthens the STING pathway response to combat cancer, by increasing the innate immune response within the tumor microenvironment. Due to a unique sensitizing technology, it grants for a highly desirable systemic administration, which supports tumor growth inhibition and limited systemic inflammatory response. In September 2019 STipe received EUR 20 million in financing.
Established in 2018.
